ProfileGDS5678 / 1416747_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 84% 87% 87% 88% 86% 86% 86% 86% 86% 86% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4549386
GSM967853U87-EV human glioblastoma xenograft - Control 26.5682486
GSM967854U87-EV human glioblastoma xenograft - Control 36.2021784
GSM967855U87-EV human glioblastoma xenograft - Control 46.7937487
GSM967856U87-EV human glioblastoma xenograft - Control 56.7233887
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5563388
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4239386
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5389986
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4952986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5059486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5595486
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6505686
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5497586
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5706586